Research found women undergoing breast reconstruction after mastectomy have goals extending beyond physical restoration. Newer nerve-preserving techniques aim to restore chest and nipple sensation but are still being studied.
The FDA has approved the combination of Venclexta (venetoclax) plus acalabrutinib as the first all-oral, fixed-duration regimen for previously untreated adults with chronic lymphocytic leukemia, based on Phase III AMPLIFY study results.
Zenyaku Kogyo obtained Japanese regulatory approval for Rituxan (rituximab) as a treatment for autoimmune hemolytic anemia, a government-designated intractable disease. The approval follows a public knowledge-based application submitted in August 2025.
FLASH radiotherapy delivers therapeutic radiation doses in fractions of a second at rates exceeding 40 Gy per second, potentially reducing normal tissue damage while maintaining tumor control through altered oxygen dynamics.
Scientists at UC San Diego have identified N4BP2 as the enzyme responsible for chromothripsis, a chaotic chromosome-shattering event seen in about one in four cancers that enables rapid tumor evolution and treatment resistance.
Monthly patent reviews from April through December 2025 highlight notable drug discovery IP disclosures across targeted protein degradation, small molecule modulators, and emerging therapeutic targets in oncology, immunology, and neurology.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06945432 |
Comparing 68Ga-CTR-FAPI and 18F-FDG PET/ CT in Cancer Detection |
COMPLETED | |
| NCT06186427 |
A Novel 68Ga Labeled FAP Ligand PET/CT in Patients With Various Malignant Tumors |
RECRUITING | NA |
| NCT05733091 |
Assessment of Functional and Symptom Outcomes for Survivors of Paranasal Sinus, Nasopharyngeal and Skull Base Tumors |
RECRUITING | |
| NCT05697406 |
HP Pyruvate MRI in Cancers |
RECRUITING | PHASE1/PHASE2 |
| NCT05431582 |
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors |
WITHDRAWN | PHASE1 |
| NCT05308407 |
POWER UP: Participating Online While Exercising to Recover Using Play |
TERMINATED | NA |
| NCT05103969 |
Cohort of Tumors With POLE/D1 Mutation |
RECRUITING | |
| NCT05103358 |
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT04977739 |
Research on the Application and Mechanism of New Biological Probes in Biomedicine |
COMPLETED | |
| NCT04950959 |
XACT ACE Observational Registry |
RECRUITING |
